To examine the effect of nebulized furosemide as an adjunct to the conventional treatment of patients with COPD exacerbation in an emergency department.
METHODS:
In this randomized double-blinded clinical trial, patients with COPD exacerbation were randomized to receive 40 mg nebulized furosemide or placebo as an adjunct to the conventional treatments. We recorded changes in dyspnea severity (measured with a visual analog scale), FEV1, arterial blood gas measurements, blood pressure, heart rate, and breathing frequency at baseline and 1 hour after treatment.
RESULTS:
We randomized 100 patients, whose mean age was 73.1 ± 8.7 y. The measured variables all improved significantly in both groups. FEV1, dyspnea, pH, mean blood pressure, and heart rate improved significantly more in the furosemide group.
CONCLUSIONS:
Nebulized furosemide benefits patients with COPD exacerbation.
RabeKF, HurdS, AnzuetoA, BarnesPJ, BuistSA, CalverleyP, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 2007; 176(6):532-555.
2.
FromerL, CooperCB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract, 2008; 62(8):1219-1236.
3.
OraJ, JensenD, O'DonnellDE. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. Curr Opin Pulm Med, 2010; 16(2):144-149.
4.
SeamarkDA, SeamarkCJ, HalpinDM. Palliative care in chronic obstructive pulmonary disease: a review for clinicians. J R Soc Med, 2007; 100(5):225-233.
5.
HortonR, RockerG. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Curr Opin Support Palliat Care, 2010; 4(2):56-62.
6.
UndemBJ, KollarikM. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2005; 2(4):355-360; discussion 371-352.
7.
UronisHE, CurrowDC, AbernethyAP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis, 2006; 1(3):289-304.
KalletRH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care, 2007; 52(7):900-910.
10.
SudoT, HayashiF, NishinoT. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med, 2000; 162(3 Pt 1):971-975.
11.
MoosaviSH, BinksAP, LansingRW, TopulosGP, BanzettRB, SchwartzsteinRM. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol, 2007; 156(1):1-8.
12.
NishinoT, IdeT, SudoT, SatoJ. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med, 2000; 161(6):1963-1967.
13.
Rodriguez VazquezJC, Pino AlfonsoPP, Gassiot NunoC, Paez PratsI, Fernandez ManzanoE. Assessment of the bronchodilator effect of inhaled furosemide compared to salbutamol in asthmatic patients. J Investig Allergol Clin Immunol, 1998; 8(2):115-118.
14.
ShimoyamaN, ShimoyamaM. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage, 2002; 23(1):73-76.
15.
KoharaH, UeokaH, AoeK, MaedaT, TakeyamaH, SaitoR, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage, 2003; 26(4):962-967.
16.
OngKC, KorAC, ChongWF, EarnestA, WangYT. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004; 169(9):1028-1033.
17.
JensenD, AmjadiK, Harris-McAllisterV, WebbKA, O'DonnellDE. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax, 2008; 63(7):606-613.
18.
CurrowDC, WardAM, AbernethyAP. Advances in the pharmacological management of breathlessness. Curr Opin Support Palliat Care, 2009; 3(2):103-106.
19.
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1995; 152(5 Pt 2):S77-121.
20.
NiewoehnerDE, CollinsD, ErblandML. Relation of FEV1 to clinical outcomes during exacerbation of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med, 2000; 161(4 Pt 1):1201-1205.
21.
KhoukazG, GrossNJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Am J Respir Crit Care Med, 1999; 160(3):1028-1030.
22.
WhaleCI, SovaniMP, MortimerK, OborneJ, CooperS, HarrisonTW, et al. Effects of rac-albuterol on arterial blood gases in patients with stable hypercapnic chronic obstructive pulmonary disease. Br J Clin Pharmacol, 2006; 62(2):153-157.
23.
AndoF, RuggeriP, GirbinoG, CazzolaM. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. Respir Med, 2008; 102(6):815-818.
24.
StephensonA, SeitzD, BellCM, GruneirA, GershonAS, AustinPC, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med, 2011; 171(10):914-920.
25.
BrijkerF, HeijdraYF, van den ElshoutFJ, FolgeringHT. Discontinuation of furosemide decreases PaCO2 in patients with COPD. Chest, 2002; 121(2):377-382.
26.
MinowaY, IdeT, NishinoT. Effects of inhaled furosemide on CO2 ventilatory responsiveness in humans. Pulm Pharmacol Ther, 2002; 15(4):363-368.
